🇺🇸 FDA
Patent

US 9481692

Heterocyclic modulators of HIF activity for treatment of disease

granted A61KA61K31/4245A61K31/427

Quick answer

US patent 9481692 (Heterocyclic modulators of HIF activity for treatment of disease) held by The Board of Regents of the University of Texas System expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/4245, A61K31/427, A61K31/437, A61K31/4439